ReviewHuman vaccines & immunotherapeutics2016
Vaccine-preventable infections in Systemic Lupus Erythematosus.
Review in Human vaccines & immunotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 37 citations in OpenAlex.
- Safety and immunogenicity of influenza A(H3N2) component vaccine in juvenile systemic lupus erythematosus.Advances in rheumatology (London, England) · 2023Trial
- Vaccination practices and perceptions among physicians treating autoimmune rheumatic diseases in Italy: a cross-sectional survey.Internal and emergency medicine · 2026Article
- Markers of Antiviral Response in SLE Patients After Vaccination Against SARS-CoV-2.International journal of molecular sciences · 2025Article
- The Severity of COVID-19 in Systemic Lupus Erythematosus Patient.Infectious disorders drug targets · 2025Review
- Challenges in Diagnosis of COVID-19 Pneumonia under Ocrelizumab and De-Risking Strategies in Multiple Sclerosis-The Elephant Is (Still) in the Room.Microorganisms · 2024Article
- Global population surpasses eight billion: Are we ready for the next billion?AIMS public health · 2023Article
- SARS-CoV-2 infection risk is higher in vaccinated patients with inflammatory autoimmune diseases or liver transplantation treated with mycophenolate due to an impaired antiviral immune response: results of the extended follow up of the RIVALSA prospective cohort.Frontiers in immunology · 2023Observational
- Favorable antibody responses to human coronaviruses in children and adolescents with autoimmune rheumatic diseases.Med (New York, N.Y.) · 2021Article
- Evaluation of systemic lupus erythematosus disease activity using anti-α-enolase antibody and RDW.Clinical and experimental medicine · 2021Article
- Pneumococcal Polysaccharide Vaccine Ameliorates Murine Lupus.Frontiers in immunology · 2019Article
- Insufficient vaccination rates in patients with systemic lupus erythematosus in a German outpatient clinic.Zeitschrift fur Rheumatologie · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic Lupus Erythematosus (SLE) is characterized by abnormal autoantibody production and clearance. Infections are among the most important causes of morbidity and mortality in SLE patients; they have an increased frequency of severe bacterial and viral infections possibly due to inherited genetic and immunologic defects and to immunosuppressive therapies. In addition, infectious agents can switch on lupus disease expression and activity. Among the strategies to reduce the risk of infection, vaccination can be considered the most reliable option. Most vaccines are effective and safe in SLE patients, although in certain cases immunogenicity may be sub-optimal and vaccination can trigger a flare. Although these issues are currently unresolved, the risk benefit balance is in favor for vaccination to reduce the risk of infection in SLE patients. In the present review we discuss the preventive strategies currently recommended to reduce bacterial and viral infections in SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.